Clinical Trials & Medical Discoveries

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

by

IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with treatment of bipolar depression RADNOR, Pa., Aug. 30, 2023 /PRNewswire/ – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced submission an Investigational New … Read more

Исследование показало, что лечение аденомы простаты с iTind действует более четырех лет USA – Pусский USA – English USA – Deutsch

by

ГАМБУРГ, Германия, 13 июля 2023 г /PRNewswire/ — Olympus Corporation, международная компания в области медицинских технологий, объявила о публикации данных исследования, свидетельствующих о том, что минимально инвазивная терапия iTind™ позволяет надолго, более чем на четыре года, облегчить состояние людей, страдающих от симптомов увеличенной простаты, известной также как ДГПЖ. The iTind™ procedure involves the placement of … Read more

CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine

by

Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells PLEASANTON, Calif., July 5, 2023 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its single-cell genomic technologies were used in a study published in the journal Nature Medicine about new gene signatures that explain why some … Read more

Wider Search Needed to Better Treat Eosinophilic Food Allergy

by

Eliminating eosinophils not enough to improve outcomes for eosinophilic gastritis. Tweet this These paradigm-shifting Phase 2 clinical trial results were published online June 16, 2023, in The Lancet Gastroenterology & Hepatology. “Our findings suggest that the mechanisms driving this disease are in large part independent of excessive eosinophil production. That means our attention should turn … Read more

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

by

HEFEI, China, June 16, 2023 /PRNewswire/ — TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling … Read more

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

by

NANJING, China, June 16, 2023 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs” or “Company”) today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration). At … Read more

Studie zeigt Auswirkungen der Luftverschmutzung auf die Atemwege von Elitesportlern in der frühen Karriere

by

HAMBURG, Deutschland, 16. Juni 2023 /PRNewswire/ — Eine kürzlich in Belgien durchgeführte Studie hat die potenziellen Auswirkungen der Luftverschmutzung auf die Atemwege von Spitzensportlern in ihrer Frühkarriere aufgezeigt. Während körperliche Betätigung bekanntermaßen die allgemeine Gesundheit verbessert, deutet die Studie darauf hin, dass intensive körperliche Aktivität in einer verschmutzten Umgebung als Stressfaktor für die Atemwegsbarriere wirken … Read more

Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

by

More Patients Added to Phase 1 Trial Following Encouraging Early Results ROCHESTER, Minn., June 14, 2023 /PRNewswire/ — Vyriad, Inc., announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the safety and efficacy of Voyager-V1 (VSV-hIFNbeta-NIS) in patients with peripheral T-cell lymphoma (PTCL) following encouraging initial results1. Voyager-V1 is an investigational therapy … Read more

Tetra Pharm Technologies annonce la réussite du test in vitro de libération d’un nouveau composé analgésique

by

La société de biotechnologie danoise Tetra Pharm Technologies annonce les résultats prometteurs des essais précliniques de son médicament antidouleur – TPT0301. COPENHAGUE, Danemark, 13 juin 2023 /PRNewswire/ — Dans une récente étude in vitro du TPT0301, la nouvelle technologie d’administration de médicaments de Tetra Pharm Technologies a été comparée à des formules plus couramment utilisées pour … Read more

Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform

by

Class II clearance expands the patient population that can be managed  Companies working with Huma’s platform can now launch algorithm innovations more quickly in a compliant and de-risked manner, democratising digital health innovation across the industry Clearance was granted through the FDA’s joint eSTAR programme which aims to increase the efficiency of regulation through digitalisation NEW YORK … Read more